切换导航
  • 比较产品
我的购物车

若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

EasySep™人Naïve CD8+ T细胞分选试剂盒 II

人Naïve CD8+ T细胞的免疫磁珠负选
率先评论此产品
添加并比较

产品号 #（选择产品）

产品号 #17968_C

人Naïve CD8+ T细胞的免疫磁珠负选

产品优势

  • 快捷、操作简单，且无需分离柱
  • 纯度高达97%
  • 获得的活细胞无标记     

产品组分包括

  • EasySep™人 Naïve CD8+ T细胞分选试剂盒 II（产品号 #17968）
    • EasySep™人Naïve CD8+ T细胞分选抗体混合物，1 mL
    • EasySep™ Dextran RapidSpheres™ 磁珠，1 x 1 mL
  • RoboSep™人  Naïve CD8+ T细胞分选试剂盒 II（产品号 #17968RF）
    • EasySep™人Naïve CD8+ T细胞分选抗体混合物 ，1 mL
    • EasySep™ Dextran RapidSpheres™ 磁珠，1 x 1 mL
    • RoboSep™ 缓冲液（产品号 #20104）
    • RoboSep™过滤吸头（产品号 #20125）
main product photo
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
专为您的实验方案打造的产品
要查看实验方案所需的所有配套产品，请参阅《实验方案与技术文档》。
  1. EasySep™ Magnet
    EasySep™ Magnet

    Magnet for column-free immunomagnetic separation

  2. EasySep™ Buffer
    EasySep™ Buffer

    Cell separation buffer

总览
实验数据
产品说明书及文档
应用领域
相关材料与文献
相关产品

总览

使用EasySep™人Naïve CD8+ T细胞分选试剂盒 II，通过免疫磁珠负选，可轻松高效地从新鲜人外周血单个核细胞（PBMC）样本中分离出高纯度初始CD8+ T细胞(CD8+CD45RA+CCR7+且CD45RO-CD57-CD56-)。EasySep™结合了单克隆抗体的特异性和无柱磁性系统的简便性，迄今已广泛应用于发表的研究中超过20年。    

在此 EasySep™负选过程中，非目标细胞通过抗体复合物与磁珠标记。表达以下标记物的非目的细胞通过抗体复合物和磁珠标记被靶向去除：CD4、CD14、CD16、CD19、CD20、CD36、CD56、CD94、CD123、CD244、IgM、GlyA、TCRγδ、CD45RO及CD57。通过EasySep™磁极将被磁珠标记的细胞与未被标记的目的细胞分离，接着简单地将目的细胞倾倒或吸取至一个新的试管中。仅需11分钟磁珠分选，获得的初始CD8+ T细胞即可用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

该产品可替代EasySep™人CD8+ T细胞富集试剂盒 (产品号 #19158) 以进行更快的 细胞分选。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选 。或选择即用型、符合伦理规范的冻存人外周血原代CD8+CD45RA+ T细胞，该细胞通过EasySep™人Naïve CD8+ T细胞分选试剂盒II分离获得。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

在此 EasySep™负选过程中，非目标细胞通过抗体复合物与磁珠标记。表达以下标记物的非目的细胞通过抗体复合物和磁珠标记被靶向去除：CD4、CD14、CD16、CD19、CD20、CD36、CD56、CD94、CD123、CD244、IgM、GlyA、TCRγδ、CD45RO及CD57。通过EasySep™磁极将被磁珠标记的细胞与未被标记的目的细胞分离，接着简单地将目的细胞倾倒或吸取至一个新的试管中。仅需11分钟磁珠分选，获得的初始CD8+ T细胞即可用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

该产品可替代EasySep™人CD8+ T细胞富集试剂盒 (产品号 #19158) 以进行更快的 细胞分选。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选 。或选择即用型、符合伦理规范的冻存人外周血原代CD8+CD45RA+ T细胞，该细胞通过EasySep™人Naïve CD8+ T细胞分选试剂盒II分离获得。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

在此 EasySep™负选过程中，非目标细胞通过抗体复合物与磁珠标记。表达以下标记物的非目的细胞通过抗体复合物和磁珠标记被靶向去除：CD4、CD14、CD16、CD19、CD20、CD36、CD56、CD94、CD123、CD244、IgM、GlyA、TCRγδ、CD45RO及CD57。通过EasySep™磁极将被磁珠标记的细胞与未被标记的目的细胞分离，接着简单地将目的细胞倾倒或吸取至一个新的试管中。仅需11分钟磁珠分选，获得的初始CD8+ T细胞即可用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

该产品可替代EasySep™人CD8+ T细胞富集试剂盒 (产品号 #19158) 以进行更快的 细胞分选。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选 。或选择即用型、符合伦理规范的冻存人外周血原代CD8+CD45RA+ T细胞，该细胞通过EasySep™人Naïve CD8+ T细胞分选试剂盒II分离获得。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

在此 EasySep™负选过程中，非目标细胞通过抗体复合物与磁珠标记。表达以下标记物的非目的细胞通过抗体复合物和磁珠标记被靶向去除：CD4、CD14、CD16、CD19、CD20、CD36、CD56、CD94、CD123、CD244、IgM、GlyA、TCRγδ、CD45RO及CD57。通过EasySep™磁极将被磁珠标记的细胞与未被标记的目的细胞分离，接着简单地将目的细胞倾倒或吸取至一个新的试管中。仅需11分钟磁珠分选，获得的初始CD8+ T细胞即可用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

该产品可替代EasySep™人CD8+ T细胞富集试剂盒 (产品号 #19158) 以进行更快的 细胞分选。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选 。或选择即用型、符合伦理规范的冻存人外周血原代CD8+CD45RA+ T细胞，该细胞通过EasySep™人Naïve CD8+ T细胞分选试剂盒II分离获得。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
 
亚型
细胞分选试剂盒
 
细胞类型
T 细胞，T 细胞，CD8+
 
种属
人
 
样本来源
PBMC
 
筛选方法
Negative
 
应用
细胞分选
 
品牌
EasySep，RoboSep
 
研究领域
免疫
 

查看更多 显示更少

实验数据

Figure 1. Typical EasySep™ Human Naive CD8 T Cell Isolation Profile

Starting with fresh PBMCs, the naïve CD8+ T cell content (CD8+CD45RA+CCR7+ and CD45RO-CD57-CD56-) of the isolated fraction is typically 93.7 ± 2.4% (mean ± SD), using the purple EasySep™ Magnet. In the above example, the purities of the start and final isolated fractions are 6.8% and 94.2%, respectively.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
RoboSep™ Human Naïve CD8+ T Cell Isolation Kit II
Catalog #
17968RF
Lot #
All
Language
English
Document Type
Product Information Sheet
Product Name
EasySep™ Human Naïve CD8+ T Cell Isolation Kit II
Catalog #
17968
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
RoboSep™ Human Naïve CD8+ T Cell Isolation Kit II
Catalog #
17968RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
RoboSep™ Human Naïve CD8+ T Cell Isolation Kit II
Catalog #
17968RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Product Name
RoboSep™ Human Naïve CD8+ T Cell Isolation Kit II
Catalog #
17968RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
EasySep™ Human Naïve CD8+ T Cell Isolation Kit II
Catalog #
17968
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
EasySep™ Human Naïve CD8+ T Cell Isolation Kit II
Catalog #
17968
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area
Workflow Stages

相关材料与文献

技术资料 (9)

EasySep™ Cell Separation Technology
Brochure
EasySep™ Cell Separation Technology
Tools for Your Immunology Research
Brochure
Tools for Your Immunology Research
Frequencies of Human Cell Types in Blood-Related Sources
Wallchart
Frequencies of Human Cell Types in Blood-Related Sources
Antigen Processing and Presentation
Wallchart
Antigen Processing and Presentation
Human Immune Cytokines
Wallchart
Human Immune Cytokines
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology
1:13
Video
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
1:57
Video
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
How to Isolate PBMCs from Whole Blood Using Density Gradient Centrifugation (Ficoll™ or Lymphoprep™)
1:37
Video
How to Isolate PBMCs from Whole Blood Using Density Gradient Centrifugation (Ficoll™ or Lymphoprep...
Isolation of Untouched Human Naive and Memory CD8 T Cells
Scientific Poster
Isolation of Untouched Human Naive and Memory CD8 T Cells

文献 (3)

Induction of memory-like CD8+ T cells and CD4+ T cells from human naive T cells in culture. Y. Tokumoto et al. Clinical and experimental immunology 2022 jan

Abstract

Memory T cells are crucial players in vertebrate adaptive immunity but their development is incompletely understood. Here, we describe a method to produce human memory-like T cells from naive human T cells in culture. Using commercially available human T-cell differentiation kits, both purified naive CD8+ T cells and purified naive CD4+ T cells were activated via T-cell receptor signaling and appropriate cytokines for several days in culture. All the T-cell activators were then removed from the medium and the cultures were continued in hypoxic condition (1% O2 atmosphere) for several more days; during this period, most of the cells died, but some survived in a quiescent state for a month. The survivors had small round cell bodies, expressed differentiation markers characteristic of memory T cells and restarted proliferation when the T-cell activators were added back. We could also induce memory-like T cells from naive human T cells without hypoxia, if we froze the activated T cells or prepared the naive T cells from chilled filter buffy coats.
View publication
Tbc1d10c is a selective, constitutive suppressor of the CD8 T-cell anti-tumor response. A. O. Cohen et al. Oncoimmunology 2022

Abstract

Cancer immunotherapy approaches target signaling pathways that are highly synonymous between CD4 and CD8 T-cell subsets and, therefore, often stimulate nonspecific lymphocyte activation, resulting in cytotoxicity to otherwise healthy tissue. The goal of our study was to identify intrinsic modulators of basic T lymphocyte activation pathways that could discriminately bolster CD8 anti-tumor effector responses. Using a Tbc1d10c null mouse, we observed marked resistance to a range of tumor types conferred by Tbc1d10c deficiency. Moreover, tumor-bearing Tbc1d10c null mice receiving PD-1 or CTLA-4 monotherapy exhibited a 33% or 90% cure rate, respectively. While Tbc1d10c was not expressed in solid tumor cells, Tbc1d10c disruption selectively augmented CD8 T-cell activation and cytotoxic effector responses and adoptive transfer of CD8 T cells alone was sufficient to recapitulate Tbc1d10c null tumor resistance. Mechanistically, Tbc1d10c suppressed CD8 T-cell activation and anti-tumor function by intersecting canonical NF-$\kappa$B pathway activation via regulation of Map3k3-mediated IKK$\beta$ phosphorylation. Strikingly, none of these cellular or molecular perturbations in the NF-$\kappa$B pathway were featured in Tbc1d10c null CD4 T cells. Our findings identify a Tbc1d10c-Map3k3-NF-$\kappa$B signaling axis as a viable therapeutic target to promote CD8 T-cell anti-tumor immunity while circumventing CD4 T cell-associated cytotoxicity and NF-$\kappa$B activation in tumor cells.
View publication
Efficient derivation of chimeric-antigen receptor-modified TSCM cells. E. Kranz et al. Frontiers in immunology 2022

Abstract

Chimeric-antigen receptor (CAR) T-cell immunotherapy employs autologous-T cells modified with an antigen-specific CAR. Current CAR-T manufacturing processes tend to yield products dominated by effector T cells and relatively small proportions of long-lived memory T cells. Those few cells are a so-called stem cell memory T (TSCM) subset, which express na{\{i}}ve T-cell markers and are capable of self-renewal and oligopotent differentiation into effector phenotypes. Increasing the proportion of this subset may lead to more effective therapies by improving CAR-T persistence; however there is currently no standardized protocol for the effective generation of CAR-TSCM cells. Here we present a simplified protocol enabling efficient derivation of gene-modified TSCM cells: Stimulation of na{\"{i}}ve CD8+ T cells with only soluble anti-CD3 antibody and culture with IL-7 and IL-15 was sufficient for derivation of CD8+ T cells harboring TSCM phenotypes and oligopotent capabilities. These in-vitro expanded TSCM cells were engineered with CARs targeting the HIV-1 envelope protein as well as the CD19 molecule and demonstrated effector activity both in vitro and in a xenograft mouse model. This simple protocol for the derivation of CAR-TSCM cells may facilitate improved adoptive immunotherapy."
View publication
View All Publications

更多信息

更多信息
种属 Human
Magnet Compatibility • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
样本来源 PBMC
Selection Method Negative
标记抗体
  1. 抗人CD56抗体，克隆HCD56
    抗人CD56抗体，克隆HCD56

    小鼠单克隆IgG1抗体，抗人CD56 （NCAM）

  2. 抗人CD8a抗体，克隆RPA-T8
    抗人CD8a抗体，克隆RPA-T8

    小鼠单克隆IgG1抗体，抗人、恒河猴、食蟹猴CD8a

  3. 抗人CD45RO抗体，克隆UCHL1
    抗人CD45RO抗体，克隆UCHL1

    小鼠单克隆IgG2a抗体，抗人、黑猩猩、普通狨猴CD45RO

质量保证:

产品仅供研究使用，不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息，请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.